After an intense and acrimonious months long battle for a hostile takeover of Allergan, Bill Ackman, who owns a 9.7% stake in the company, finally gave up his battle to convene a special shareholders’ meeting on December 18th, according to Bidness etc.
Allergan had been fighting off a hostile takeover from Valeant and Ackman for months, because CEO David Pyott said the offer severely undervalued Allergan. Valeant kept upping its offer, with a rumor that the forced meeting that Ackman was planning would give it a $200 a share offer. Activis, however, jumped in recently with a bid that valued the company even higher at $66 billion.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Ackman is no longer pushing for a shareholder meeting and says he is happy for Activis. He said, “We congratulate Actavis and Allergan on their announced transaction. As a result of the deal, we are withdrawing our special meeting request.”
So as an Allergan shareholder, Ackman is happy. Whether the deal is his baby or not.
